ArticleEndocrine2026
Hepcidin concentration and effect on iron homeostasis in patients with adrenocortical carcinoma and benign adrenal lesions - a pilot study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe evaluation of hepcidin concentration and iron (Fe) homeostasis parameters in patients with: adrenocortical carcinoma (ACC) to compared to control subjects (CS) and in ACC patients before surgical or pharmacological treatment (ACC-nt) to ACC patients during mitotane therapy (ACC-t).
methodsWe enrolled 33 adult patients with histopathologically confirmed non-adenoma of adrenal gland. Each patient underwent hepcidin, Fe metabolism parameters and biochemical evaluation. Hepcidin levels were measured using the Hepcidin 25 (bioactive) hs ELISA, a highly sensitive enzyme immunoassay designed for the quantitative in vitro diagnostic determination (DRG Instruments GmbH, Germany). The study group was consisted of: 13 patients (10 females) with ACC following adrenal surgery undergoing mitotane therapy (ACC-t), 9 patients (6 females) with ACC who had not received prior pharmacological or surgical treatment (ACC-nt) and 11 patients (6 females) with histologically benign adrenal tumors who underwent subsequent surgery (CS).
resultsThe patients with ACC present higher median values of hepcidin compared to CS: [13.9 (7.6–24.3) vs. 12.3 (1.5–20.9) ng/mL, p > 0.052], while in ACC-nt group was lower than in ACC-t [11.1 (8.3–24.3) vs. 14.9 (7.6–24.3) ng/mL, p = 0.053]. We noticed statistically significant differences between ACC and CS group: RBC-m, HGB, MCH, MCHC, Fe-m concentration and correlations between: hepcidinACC vs. ferritin-maleACC, hepcidinACC vs. ferritin-femaleACC, hepcidinACC−nt vs. ferritin-maleACC−nt, hepcidinACC−nt vs. ferritin-femaleACC−nt, hepcidinCS vs. ferritin-femaleCS and hepcidinCS vs. MCVCS.
conclusionsIn patients with ACC the neoplastic process increases hepcidin level, which leads to decreased hematological parameters, while treatment improve Fe homeostasis.
Indexed as
Identifiers
41627578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.